Loading…
Oragenics, Inc. is projected to rise to $0.6551 by 2027, a +12% move from its current price of $0.5826. OGEN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.5672 | $0.5827 | $0.5985 | +0.01% |
| Jul 13 | $0.561 | $0.5827 | $0.6053 | +0.02% |
| Jul 14 | $0.5563 | $0.5828 | $0.6106 | +0.03% |
| Jul 15 | $0.5523 | $0.5828 | $0.6151 | +0.04% |
| Jul 16 | $0.5489 | $0.5829 | $0.619 | +0.05% |
| Jul 17 | $0.5458 | $0.583 | $0.6227 | +0.06% |
| Jul 18 | $0.543 | $0.583 | $0.626 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.543 | $0.583 | $0.626 | +0.07% |
| Week 2 | $0.5276 | $0.5835 | $0.6452 | +0.15% |
| Week 3 | $0.5162 | $0.5839 | $0.6605 | +0.22% |
| Week 4 | $0.5068 | $0.5843 | $0.6737 | +0.29% |
| Week 5 | $0.4987 | $0.5847 | $0.6856 | +0.37% |
| Week 6 | $0.4916 | $0.5852 | $0.6966 | +0.44% |
| Week 7 | $0.4851 | $0.5856 | $0.707 | +0.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Oragenics, Inc., a development-stage healthcare company in the United States, engages in the research and development of nasal delivery pharmaceutical therapies for neurological conditions and infectious diseases. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
Oragenics, Inc. (OGEN) is currently trading at $0.588 per share and has a market capitalization of $2.65M. By market size, it remains a micro-cap stock, ranking 5456.
The near-term technical setup shows a BEARISH sentiment, with RSI(14) at 50. The stock trades its 50-day simple moving average at $0.6132 and its 200-day simple moving average at $0.8739.
This places near-term price pressure around the $0.55 support and $0.62 resistance levels. Forecasts project gradual appreciation with the 2026 average price at $0.588, rising to a 2032 average of $0.7614 and a 2050 average of $1.82, with a 2050 max of $3.52. ROI figures progress from 0% in 2026 to 208.8% by 2050, with varying mid-term gains in between.
A major floor 14.2% below — a decisive break under it would weaken the trend.
The nearest floor, 5.6% below — buyers have tended to step in here.
The nearest ceiling, 6.4% above — a clean break opens room to run.
A major ceiling 68.2% above — clearing it would confirm fresh momentum.
Key OGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.582 | Buy | $0.5854 | Sell |
| MA 10 | $0.587 | Sell | $0.5862 | Sell |
| MA 20 | $0.5915 | Sell | $0.5893 | Sell |
| MA 50 | $0.5944 | Sell | $0.6069 | Sell |
| MA 100 | $0.6535 | Sell | $0.6968 | Sell |
| MA 200 | $0.8366 | Sell | $1.82 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.48 | Neutral |
| Stoch RSI (14) | 63.54 | Neutral |
| CCI (20) | -7.09 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 0.00 | Neutral |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | -0.11 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 55.03 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | -12.00 | Sell |
| Hull MA (9) | 0.58 | Buy |
| ADX (14) | 7.46 | Neutral |
| ATR (14) | 0.01 | Info |
The 30-day technical picture shows a BEARISH tilt, with the RSI(14) at 50. The stock sits near its 50-day moving average of $0.6132 and well below the 200-day moving average of $0.8739. Near-term support is at $0.55, with resistance at $0.62.
The 30-day price range spans from a low of $0.4797 to a high of $0.7207, signaling volatility and a narrow trading band near current levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.50 | $0.5826 | $0.7365 | 0% | Neutral | |
| $0.5222 | $0.6551 | $0.869 | +12% | Neutral | |
| $0.5125 | $0.6608 | $0.9091 | +13% | Neutral | |
| $0.4547 | $0.5998 | $0.8491 | +3% | Neutral | |
| $0.46 | $0.619 | $0.8976 | +6% | Neutral | |
| $0.4509 | $0.618 | $0.9151 | +6% | Neutral | |
| $0.512 | $0.7138 | $1.08 | +23% | Bullish | |
| $0.5891 | $0.8344 | $1.28 | +43% | Bullish | |
| $0.5365 | $0.7715 | $1.20 | +32% | Bullish | |
| $0.5177 | $0.7554 | $1.20 | +30% | Bullish | |
| $0.6716 | $1.05 | $1.76 | +80% | Bullish | |
| $0.9515 | $1.66 | $3.05 | +185% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.50 | $0.5826 | $0.6973 | +0.00% |
| August 2026 | $0.4878 | $0.5757 | $0.6975 | -1.19% |
| September 2026 | $0.4951 | $0.5882 | $0.7205 | +2.18% |
| October 2026 | $0.5067 | $0.6056 | $0.7486 | +2.96% |
| November 2026 | $0.4951 | $0.5947 | $0.7408 | -1.81% |
| December 2026 | $0.4865 | $0.5871 | $0.7365 | -1.27% |
Click any year to see its month-by-month OGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Oragenics, Inc.'s 2026 outlook centres on $0.5826, within a $0.50 to $0.7365 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, OGEN could reach as high as $0.869, with a base case around $0.6551 and support toward $0.5222 — roughly +12% from $0.5826. A consolidation phase looks the most probable path here.
Expect OGEN to range from $0.5125 to $0.9091 through 2028. The $0.6608 average target implies a +13% move from current prices. That is up +1% on the projected 2027 average. Price action looks broadly range-bound.
The OGEN price prediction for 2029 points to an average of $0.5998 (low $0.4547, high $0.8491) — a potential gain of +3% on today's $0.5826. A consolidation phase looks the most probable path here.
In 2030, OGEN is projected to trade between $0.46 and $0.8976, averaging $0.619 — a potential gain of +6% from today's $0.5826. That is up +3% on the projected 2029 average. Price action looks broadly range-bound.
Oragenics, Inc.'s 2031 outlook centres on $0.618, within a $0.4509 to $0.9151 range. That is 0% versus the projected 2030 average. That marks a +6% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, OGEN could reach as high as $1.08, with a base case around $0.7138 and support toward $0.512 — roughly +23% from $0.5826. Momentum favours further upside here.
Expect OGEN to range from $0.5891 to $1.28 through 2033. The $0.8344 average target implies a +43% move from current prices. That is up +17% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The OGEN price prediction for 2034 points to an average of $0.7715 (low $0.5365, high $1.20) — a potential gain of +32% on today's $0.5826. Momentum favours further upside here.
In 2035, OGEN is projected to trade between $0.5177 and $1.20, averaging $0.7554 — a potential gain of +30% from today's $0.5826. That is -2% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Oragenics, Inc.'s 2040 outlook centres on $1.05, within a $0.6716 to $1.76 range. That is up +39% on the projected 2035 average. That marks a +80% change versus current levels. Momentum favours further upside here.
By 2050, OGEN could reach as high as $3.05, with a base case around $1.66 and support toward $0.9515 — roughly +185% from $0.5826. Buyers look set to stay in control over this stretch.
Investing $1,000 in OGEN today (≈ 1,716.443529 OGEN) could be worth
$2,848.9
+$1,848.9 (+185%) by 2050 · US Dollar
Based on the average projected OGEN price of $1.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OGENwould be worth at today's price.
$1,000 invested in OGEN on Jul 10, 2025 (≈ 684.931489 OGEN) would be worth
$399.04
-$600.96 (-60.1%) today · 0.40× · US Dollar
Based on a OGEN entry price of $1.46 vs. today's $0.5826.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.59 | $987.46 | -1.3% |
| 1 month ago | $0.59 | $987.46 | -1.3% |
| 3 months ago | $0.6 | $971 | -2.9% |
| 6 months ago | $0.86 | $677.44 | -32.3% |
| 1 year ago | $1.46 | $399.04 | -60.1% |
| All time (5.0y) ago | $1,134 | $0.51 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OGEN forecast.
Our base-case forecast reaches $1.20 around 2050.
Implied market cap at $1.20: $5.41M
Forecasts lay out a path of gradual appreciation from the mid-to-late 2020s into the 2030s and beyond. The 2030 average price is $0.6216, with a maximum of $0.9291 and a 5.7% ROI, while the 2032–2035 window turns progressively more bullish, with 2032 average $0.7614 and a 29.5% ROI, 2033 average $0.8747 and 48.8% ROI, 2034 average $0.7787 and 32.4% ROI, and 2035 average $0.7854 and 33.6% ROI.
The bullish trend broadens into the 2040s, with 2040 averaging $1.08 and a maximum of $1.89, delivering an 83% ROI. By 2050 the forecast projects an average of $1.82 and a maximum of $3.52, with a 208.8% ROI.
These figures reflect estimated price paths and do not guarantee future results. Near-term sentiment remains NEUTRAL to BEARISH, with volatility noted at 60% annually; the upside hinges on clinical, regulatory, and market factors that could alter the trajectory.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.6216 with a min of $0.4498 and a max of $0.9291, and a 5.7% ROI, with sentiment NEUTRAL.
Forecasts indicate a neutral stance through 2026–2031, followed by bullish years from 2032 onward, with a 2050 max scenario of $3.52 and a 208.8% ROI. These are estimates and not guaranteed.
Yes. The forecast shows the max price reaching $1.19 in 2032, $1.39 in 2033, and higher later, with 2040 max $1.89 and 2050 max $3.52.
Near-term sentiment is NEUTRAL to BEARISH with a 30-day range of $0.4797 to $0.7207 and support at $0.55. Annualized volatility is 60%. These factors imply price risk and uncertainty.
The 2040 forecast shows an average price of $1.08 with a max of $1.89 and an 83% ROI, in a bullish sentiment framework.
Oragenics, Inc. Community Discussion
0Share your Oragenics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.